TransMedics Group Inc (NASDAQ:TMDX) Director David Weill purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $170,000.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $170,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
NASDAQ TMDX opened at $17.87 on Friday. The stock’s 50 day moving average price is $18.80. The company has a debt-to-equity ratio of 0.54, a current ratio of 7.33 and a quick ratio of 6.82. TransMedics Group Inc has a 52 week low of $15.74 and a 52 week high of $31.54.
TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. The business had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $6.67 million. Research analysts forecast that TransMedics Group Inc will post -2.09 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on TMDX shares. Cowen lowered their price objective on shares of TransMedics Group from $40.00 to $28.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Zacks Investment Research raised shares of TransMedics Group from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $33.00.
About TransMedics Group
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Read More: How is a Moving Average Calculated?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.